Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 13Carcinoma, Renal Cell 10Colorectal Neoplasms 9Neoplasm Metastasis 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Ovarian Epithelial 4Uveal Melanoma 3Esophageal Neoplasms 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Sezary Syndrome 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Melanoma, Cutaneous Malignant 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2

Interventions

pembrolizumab 1Taxes 1Pemetrexed 1Paclitaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Paclitaxel × Dermatologic × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡